Vizsgálati helyszín
Clinical Best Solutions Sp. z o.o. S.K.
Warsaw, 02-793, LengyelországEU-13 felzárkózó országMég nincs intézményhez kötve
- 12futó vizsgálat
- 14lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 26 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis20 vizsgálat
- 2. fázis6 vizsgálat
- Állapot
- Lezárult14 vizsgálat
- Fut, nem toboroz7 vizsgálat
- Toboroz5 vizsgálat
- Fő szponzor
- Alumis Inc2 vizsgálat
- Amgen Inc.2 vizsgálat
- Ionis Pharmaceuticals, Inc.2 vizsgálat
- MoonLake Immunotherapeutics AG2 vizsgálat
- Spyre Therapeutics, Inc.2 vizsgálat
- és még 15
Futó vizsgálatok
Meghívásos bevonás
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294· 2. fázis· Spyre Therapeutics, Inc.· Forrás
Toboroz
Confirmatory Clinical Study in Active Ulcerative Colitis
NCT07296315· 2. fázis· MRM Health NV· Forrás
Fut, nem toboroz
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa
2025-520564-17-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Fut, nem toboroz
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
2024-516652-18-00· 3. fázis· Amgen Inc.· Forrás
Fut, nem toboroz
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.
2024-515672-12-00· 3. fázis· Sun Pharmaceutical Industries Limited· Forrás
Toboroz
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395· 2. fázis· Spyre Therapeutics, Inc.· Forrás
Fut, nem toboroz
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· 3. fázis· Alumis Inc· Forrás
Toboroz
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis
2023-504724-25-00· 3. fázis· Kartos Therapeutics Inc.· Forrás
Fut, nem toboroz
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076· 3. fázis· Takeda· Forrás
Toboroz
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200· 3. fázis· Anthos Therapeutics, Inc.· Forrás
Fut, nem toboroz
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
NCT05681351· 3. fázis· Ionis Pharmaceuticals, Inc.· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Fut, nem toboroz
A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis
NCT06630559· 3. fázis· Celltrion· Forrás
Leállították
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT06685835· 2. fázis· Insmed Incorporated· Forrás
Lezárult
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT06602219· 2. fázis· DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company· Forrás
Lezárult
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa
2024-511360-87-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Lezárult
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
NCT06588738· 3. fázis· Alumis Inc· Forrás
Lezárult
A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/day versus Placebo in the Treatment of Patients with Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse
2024-516672-16-00· 3. fázis· Ab Science· Forrás
Lezárult
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864· 3. fázis· Boehringer Ingelheim· Forrás
Lezárult
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
NCT06088043· 3. fázis· Takeda· Forrás
Lezárult
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon)
2022-501538-44-00· 3. fázis· Amgen Inc.· Forrás
Lezárult
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia
NCT05610280· 3. fázis· Ionis Pharmaceuticals, Inc.· Forrás
Lezárult
The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)
NCT05162586· 2. fázis· EMD Serono Research & Development Institute, Inc.· Forrás
Lezárult
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
NCT03989206· 3. fázis· Galderma R&D· Forrás
Lezárult
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
NCT03872401· 3. fázis· Amgen· Forrás
Lezárult
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
NCT03142334· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Hibát jelzek